首页> 外文OA文献 >Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma
【2h】

Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma

机译:夹心型酶联免疫吸附测定技术的发展,用于定量血浆中大鼠和鼠凝血酶可激活的纤溶抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Altered plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) are associated with a large number of pathologies. Rat and murine models are frequently used to study the pathophysiological role of TAFI in vivo but immunological tools to quantify rat and murine TAFI are lacking. OBJECTIVE: The production of monoclonal antibodies (mAb) towards rat TAFI and the development of an ELISA for the quantification of rat and murine TAFI in plasma. METHODS AND RESULTS: Monoclonal antibodies were raised in TAFI-deficient mice towards (activated) recombinant rat TAFI. Pair-wise testing of the mAb revealed three suitable ELISA combinations, namely RT36A3F5/RT30D8-HRP, RT36A3F5/RT82F12-HRP and RT82F12/RT36A3F5-HRP. All three ELISAs are highly specific for rat and murine TAFI. TAFI concentrations in the lower ng mL(-1) range can be determined in plasma samples with a high reproducibility. Comparing TAFI antigen levels measured by these ELISAs with TAFIa activity values determined by activity based assays revealed excellent correlations (R(2) > 0.98). The average antigen levels of 20 individual rat plasma samples were 16 +/- 2 microg mL(-1) using the RT36A3F5-RT30D8-HRP, 12 +/- 2 microg mL(-1) using the RT36A3F5-RT82F12-HRP and 21 +/- 2 microg mL(-1) using the RT82F12-RT36A3F5-HRP ELISA. The determined antigen levels in rat plasma are similar to the levels reported for human plasma. CONCLUSIONS: We developed three highly specific and extremely sensitive sandwich-type ELISAs for the quantification of rat and murine TAFI in plasma. The described ELISAs will facilitate in vivo investigation on the pathophysiological role of TAFI.
机译:背景:凝血酶可激活的纤维蛋白溶解抑制剂(TAFI)的血浆水平改变与多种疾病有关。大鼠和鼠模型经常用于研究TAFI在体内的病理生理作用,但缺乏定量大鼠和鼠TAFI的免疫学工具。目的:针对大鼠TAFI的单克隆抗体(mAb)的产生以及用于定量血浆中大鼠和鼠TAFI的ELISA的发展。方法和结果:在TAFI缺陷型小鼠中针对(激活的)重组大鼠TAFI产生单克隆抗体。单克隆抗体的成对测试显示了三种合适的ELISA组合,即RT36A3F5 / RT30D8-HRP,RT36A3F5 / RT82F12-HRP和RT82F12 / RT36A3F5-HRP。所有三种ELISA对大鼠和鼠类TAFI具有高度特异性。可以在血浆样品中以较高的重现性确定较低ng mL(-1)范围内的TAFI浓度。通过这些ELISA测量的TAFI抗原水平与通过基于活性的测定法确定的TAFIa活性值进行比较,显示出极好的相关性(R(2)> 0.98)。使用RT36A3F5-RT30D8-HRP使用20种大鼠血浆样品的平均抗原水平分别为16 +/- 2 microg mL(-1),使用RT36A3F5-RT82F12-HRP和21使用12种+/- 2 microg mL(-1)使用RT82F12-RT36A3F5-HRP ELISA +/- 2 microg mL(-1)在大鼠血浆中确定的抗原水平类似于人类血浆中报道的水平。结论:我们开发了三种高度特异性和极灵敏的夹心型ELISA,用于定量血浆中大鼠和鼠类TAFI。所述的ELISA将促进体内对TAFI的病理生理作用的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号